BioVector? NCI-H446-DDP 細(xì)胞系是研究小細(xì)胞肺癌（SCLC）多藥耐藥性的核心模型，特別是針對(duì)**順鉑（Cisplatin/DDP）**的耐藥機(jī)制。

• 細(xì)胞名稱: NCI-H446-DDP (或 H446/DDP)

• 物種: 人類 (Homo sapiens)

• 疾病類型: 小細(xì)胞肺癌 (SCLC)

• 起源背景: 通過在親本細(xì)胞系 NCI-H446 中通過階梯濃度遞增誘導(dǎo)法，結(jié)合順鉑 (DDP) 長期誘導(dǎo)建立的耐藥株。

• 生物安全等級(jí): 1 (建議按 BSL-2 標(biāo)準(zhǔn)處理人源樣本)

• 耐藥特性: 對(duì)順鉑 (Cisplatin) 具有顯著的耐藥性，通常表現(xiàn)出 5-10 倍或更高的耐藥指數(shù) (Resistance Index)。

• 多藥耐藥 (MDR): 往往伴隨對(duì)阿霉素 (ADM)、長春新堿 (VCR) 等藥物的交叉耐藥。

• 分子特征:

  • 通常伴隨 P-gp (ABCB1) 或 MRP1 的表達(dá)上調(diào)。

  • 凋亡抑制因子（如 Bcl-2）表達(dá)升高。

  • DNA 修復(fù)能力增強(qiáng)。

  
  

• 主要應(yīng)用:

  • 耐藥逆轉(zhuǎn)實(shí)驗(yàn): 篩選能逆轉(zhuǎn)順鉑耐藥的小分子藥物或天然產(chǎn)物。

  • 耐藥機(jī)制研究: 研究自噬、上皮-間充質(zhì)轉(zhuǎn)化 (EMT) 或干性因子在 SCLC 耐藥中的作用。

  
  

• 形態(tài)學(xué): 類上皮狀，成團(tuán)懸浮生長或松散貼壁。

• 培養(yǎng)基: RPMI-1640 + 10% 胎牛血清 (FBS)。

• 維持耐藥性: 為了保持耐藥表型，培養(yǎng)基中通常需定期加入低濃度的順鉑（如 1.0 - 2.0 μg/mL），但在實(shí)驗(yàn)前需提前 2-3 天撤藥。

• 培養(yǎng)條件: 37 °C, 5% CO?。

• 冷凍保存: 90% FBS + 10% DMSO。

Cell Line Datasheet - English Version

• Cell Line Name: NCI-H446-DDP (also H446/DDP)

• Species: Human (Homo sapiens)

• Disease: Small Cell Lung Cancer (SCLC)

• Origin: A cisplatin-resistant subline derived from the parental NCI-H446 cell line through chronic exposure to increasing concentrations of Cisplatin (DDP).

• Biosafety Level: 1 (BSL-2 handling recommended).

• Resistance Profile: Exhibits high resistance to Cisplatin (DDP), typically with a Resistance Index (RI) 5-10 times higher than the parental line.

• Cross-Resistance: Often shows Multidrug Resistance (MDR) to other chemotherapeutics like Adriamycin (ADM) and Vincristine (VCR).

• Molecular Profile:

  • Upregulation of efflux transporters such as P-glycoprotein (P-gp) or MRP1.

  • Enhanced DNA repair mechanisms and overexpression of anti-apoptotic proteins like Bcl-2.

  
  

• Research Applications:

  • Drug Resistance Reversal: Screening compounds that can sensitise SCLC cells back to platinum-based therapy.

  • Mechanistic Studies: Investigating the roles of autophagy, EMT, or cancer stemness in SCLC chemoresistance.

  
  

• Morphology: Epithelial-like; cells tend to grow in floating clusters or loosely adherent aggregates.

• Culture Medium: RPMI-1640 supplemented with 10% FBS.

• Maintenance of Resistance: To prevent the loss of the resistant phenotype, a maintenance dose of Cisplatin (e.g., 1.0 - 2.0 μg/mL) is often added to the culture; cells should be cultured in drug-free medium for 48–72 hours prior to use in assays.

• Incubation: 37 °C with 5% CO?.

• Storage/Freezing: 90% FBS + 10% DMSO.

Supplier生產(chǎn)廠家:

BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947

E-mail: [email protected]

工作微信/QQ同號(hào): 1843439339

http://www.nedfriskphoto.com